Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
289 Leser
Artikel bewerten:
(1)

KraneShares Launches Global Carbon Strategy ETC (KRBN) on London Stock Exchange

Finanznachrichten News

LONDON, Jan. 16, 2025on the London Stock Exchange. Our London listing follows the successful listings on the Borsa Italiana and Deutsche Börse Xetra.

Exchange

TickerCurrencyListing DateSEDOLISINWKN
London ExchangeKRBN LNUSD16 Jan, 2024BSRH0B0XS2879867773Not Applicable
London ExchangeKRBP LNGBP16 Jan, 2024BR4Y040

XS2879867773Not Applicable
Borsa ItalianaKRBN IMEUR3 Oct, 2024BSTJGN8XS2879867773Not Applicable
Deutsche Börse XetraKRBN GYUSD / EUR3 Oct, 2024BSRH0H6XS2879867773A4A5Z2


The KraneShares Global Carbon Strategy ETC (KRBN) is intended to track the level of its reference index, the S&P Global Carbon Credit Index, which offers broad coverage of cap-and-trade carbon allowances by tracking the most traded carbon credit futures contracts. The S&P Global Carbon Credit Index introduces a new measure for hedging risk and going long the price of carbon while supporting responsible investing.

Currently, the index covers the major European and North American cap-and-trade programs: European Union Carbon Allowances (EUA), California Carbon Allowances (CCA), United Kingdom Carbon Allowances (UKA), Washington State Carbon Allowances (WCA), and the Regional Greenhouse Gas Initiative (RGGI), which covers the Northeast US Power Market.

"KraneShares is a global leader in carbon market ETFs. We launched the first, largest, and most liquid carbon ETF on the New York Stock Exchange in 2020 in partnership with Climate Finance Partners (CLIFI).1 We are excited to expand access to this critical market through our new KRBN ETC listing on the London Stock Exchange," said KraneShares Head of Climate Investments Luke Oliver. "We believe carbon allowances provide a compelling investment opportunity because they offer low correlations and a structural upside that does not exist in other traditional commodity allocations."

"We believe carbon allowances can play an important role in every investor's portfolio. They are structurally designed for long-term price appreciation as part of their core application of decreasing emissions," said Dr. Xiaolin Chen, Head of International at KraneShares. "Besides the potential portfolio benefits, allocating to carbon supports price discovery and liquidity in the markets, which we believe promotes sustainability and true environmental impact. We are proud to extend our KRBN ETC range, which includes Borsa Italiana and Deutsche Börse Xetra listings, to the London Stock Exchange for UK investors."

What are carbon allowances?

Compliance carbon allowances trade under cap-and-trade programs known as Emissions Trading Systems (ETS). These systems create transparent, liquid markets that are government-mandated and regulated. The value of these markets reached nearly one trillion USD in 2023.2 Carbon allowances are distinct from project-based carbon offsets and offer a market-based approach to regulating a region's emissions, with mandatory participation for specified industries. Carbon allowance supply is managed by government agencies and adjusted primarily through an annually declining cap.?

For more information on the KraneShares Global Carbon Strategy ETCor consult your financial advisor.

*Diversification does not ensure a profit or guarantee against a loss.

Citations:

  1. Data from Bloomberg as Aug 31, 2024
  2. Reuters, "Global carbon markets value hit record $909 bln last year," Feb 7, 2023.

About KraneShares

KraneShares is a specialist investment manager focused on China, Climate, and Alternative Assets. KraneShares seeks to provide innovative, high-conviction, and first-to-market strategies based on the firm and its partners' deep investing knowledge. KraneShares identifies and delivers groundbreaking capital market opportunities and believes investors should have cost-effective and transparent tools for attaining exposure to various asset classes. The firm was founded in 2013 and serves institutions and financial professionals globally. The firm is a signatory of the United Nations-supported Principles for Responsible Investment (UN PRI).

Risk Disclosures

There is no guarantee that KRBN will achieve its investment objective nor will the reference index fully or successfully hedge risk while having long exposure to the price of carbon or achieve responsible investing. Further risks relating to this investment are disclosed in the KRBN base prospectus, which along with key investor information, is available on: https://kraneshares.eu/krbnln.

This document is intended only for persons residing in jurisdictions where its distribution or availability of KRBN is consistent with local laws and KraneShares' local regulatory authorizations.

Contact:
KraneShares Investor Relations
info@kraneshares.com


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.